Catalyst Wire Dossier Catalyst Wire Dossier

BIWA 4 (99mTc- or 186Re-labeled humanised monoclonal antibody)

BIWA-4 · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BIWA 4 (99mTc- or 186Re-labeled humanised monoclonal antibody), covering 2014-07-30 to 2014-07-30. Get the full timeline:

Most recent: Clinical Trial Update: Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer [Phase 1]

See pricing